Evidence map›Paper›PMID 24413734›Full record

ArticleNature genetics2014

Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas.

Teresa Palomero, Lucile Couronné, Hossein Khiabanian, Mi-Yeon Kim, Alberto Ambesi-Impiombato, Arianne Perez-Garcia, Zachary Carpenter, Francesco Abate, Maddalena Allegretta, J Erika Haydu and 11 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 356 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
356citing papers in PubMed, 1 pooled it
42.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

356 citing papers in PubMed, 1 synthesis or guideline pooled it, 613 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. RHOA controls oncogenic B cell receptor signaling in aggressive lymphoma.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

296 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 11 institutions in 4 countries.

Teresa Palomero1] Institute for Cancer Genetics, Columbia University, New York, New York, USA. [2] Department of Pathology, Columbia University Medical Center, New York, New York, USA. [3].
Lucile Couronné1] Institute for Cancer Genetics, Columbia University, New York, New York, USA. [2].
Hossein Khiabanian1] Department of Systems Biology, Columbia University, New York, New York, USA. [2].
Mi-Yeon KimInstitute for Cancer Genetics, Columbia University, New York, New York, USA.
Alberto Ambesi-ImpiombatoInstitute for Cancer Genetics, Columbia University, New York, New York, USA.
Arianne Perez-GarciaInstitute for Cancer Genetics, Columbia University, New York, New York, USA.
Zachary CarpenterDepartment of Systems Biology, Columbia University, New York, New York, USA.
Francesco Abate1] Department of Systems Biology, Columbia University, New York, New York, USA. [2] Department of Control and Computer Engineering, Politecnico di Torino, Torino, Italy.
Maddalena AllegrettaInstitute for Cancer Genetics, Columbia University, New York, New York, USA.
J Erika HayduInstitute for Cancer Genetics, Columbia University, New York, New York, USA.
Xiaoyu JiangDivision of Hematology-Oncology, Sylvester Comprehensive Cancer Center, Miami, Florida, USA.
Izidore S Lossos1] Division of Hematology-Oncology, Sylvester Comprehensive Cancer Center, Miami, Florida, USA. [2] Department of Molecular and Cellular Pharmacology, University of Miami, Miami, Florida, USA.
Concha NicolasHematology Service, Hospital Central de Asturias, Oviedo, Spain.
Milagros BalbinMolecular Oncology Laboratory, Instituto Universitario de Oncología del Principado de Asturias, Hospital Universitario Central de Asturias, Oviedo, Spain.
Christian BastardINSERM U918, Rouen University, Centre Henri Becquerel, Rouen, France.
Govind BhagatDepartment of Pathology, Columbia University Medical Center, New York, New York, USA.
Miguel A Piris1] Pathology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain. [2] Instituto de Formacion e Investigacion Marques de Valdecilla-IFIMAV, Santander, Spain.
Elias Campo1] Hematopathology Section, Department of Pathology, Hospital Clinic, Barcelona, Spain. [2] Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.ORCID 0000000198509793
Olivier A Bernard1] INSERM U985, Villejuif, France. [2] Université Paris-Sud, Orsay, France. [3] Institut Gustave Roussy, Villejuif, France.
Raul Rabadan1] Department of Systems Biology, Columbia University, New York, New York, USA. [2] Department of Biomedical Informatics, Columbia University, New York, New York, USA.
Adolfo A Ferrando1] Institute for Cancer Genetics, Columbia University, New York, New York, USA. [2] Department of Pathology, Columbia University Medical Center, New York, New York, USA. [3] Department of Pediatrics, Columbia University Medical Center, New York, New York, USA.
Cancer Genetics (United States) · USColumbia University · USColumbia University Irving Medical Center · USSylvester Comprehensive Cancer Center · USHospital Clínic de Barcelona · ESHospital Universitario Central de Asturias · ESInserm · FRInstituto de Investigación Sanitaria del Principado de Asturias · ESMarqués de Valdecilla University Hospital · ESPolitecnico di Torino · ITUniversité Paris-Sud · FR

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Parisa Tehranifar · 1985 to 2026
$115.3M
Training Program in Nervous System TumorsK12CA090354 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI PLOTKIN, SCOTT R · 2001 to 2025
$16.3M
The Role of FBXL4 in T-cell Acute Lymphoblastic LeukemiaF30CA174099 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HAYDU, JULIE-ERIKA M · 2013 to 2015
$126k
NCI NIH HHS F30 CA174099NCI NIH HHS K12 CA090354-11NCI NIH HHS P30 CA013696
6 · The paper itself

Abstract

Peripheral T cell lymphomas (PTCLs) are a heterogeneous and poorly understood group of non-Hodgkin lymphomas. Here we combined whole-exome sequencing of 12 tumor-normal DNA pairs, RNA sequencing analysis and targeted deep sequencing to identify new genetic alterations in PTCL transformation. These analyses identified highly recurrent epigenetic factor mutations in TET2, DNMT3A and IDH2 as well as a new highly prevalent RHOA mutation encoding a p.Gly17Val alteration present in 22 of 35 (67%) angioimmunoblastic T cell lymphoma (AITL) samples and in 8 of 44 (18%) PTCL, not otherwise specified (PTCL-NOS) samples. Mechanistically, the RHOA Gly17Val protein interferes with RHOA signaling in biochemical and cellular assays, an effect potentially mediated by the sequestration of activated guanine-exchange factor (GEF) proteins. In addition, we describe new and recurrent, albeit less frequent, genetic defects including mutations in FYN, ATM, B2M and CD58 implicating SRC signaling, impaired DNA damage response and escape from immune surveillance mechanisms in the pathogenesis of PTCL.

Indexed as

Ataxia Telangiectasia Mutated ProteinsBase SequenceCD58 AntigensComputational BiologyDioxygenasesDNA-Binding ProteinsDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3AEpigenesis, GeneticEscherichia coliExomeFluorescent Antibody TechniqueHEK293 CellsHigh-Throughput Nucleotide SequencingHumansIsocitrate DehydrogenaseAtaxia Telangiectasia Mutated ProteinsATM protein, humanCD58 AntigensDioxygenasesDNA-Binding ProteinsDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNMT3A protein, humanFYN protein, humanIDH2 protein, humanIsocitrate DehydrogenaseProto-Oncogene ProteinsProto-Oncogene Proteins c-fynrhoA GTP-Binding ProteinRHOA protein, humanTET2 protein, human

Identifiers

PMID24413734
PMCPMC3963408
OpenAlexW4233431843

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.